New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 14, 2012
10:55 EDTABT, ABT, CELG, CELG, GILD, GILD, INFI, INFI, PCYC, PCYC, PFE, PFE, RHHBY, RHHBY, SGEN, SGENLeerink's biotech analyst holds a post-ASH update conference call
Biotech Analyst Liang discusses new agents for lymphomas including new data on kinase inhibitors Ibrutinib (PCYC), GS-1101 (GILD), IPI-145 (INFI), Bcl-2 inhibitor ABT-199 (ABT/Roche) on the Analyst/Industry conference call to be held on December 14 at 11 am.
News For ABT;CELG;GILD;INFI;PCYC;PFE;RHHBY;SGEN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
July 15, 2015
07:43 EDTCELGReceptos volatility flat into Celgene acquiring for $7.2B
Subscribe for More Information
07:09 EDTCELGCelgene may face rival bidder for Receptos, says Wedbush
Wedbush analyst Liana Moussatos believes another bidder may seek to acquire Receptos (RCPT), which has agreed to a $232 per share takeover deal with Celgene (CELG), noting that she previously estimated Receptos could be valued at $348 per share, or about $10.9B, in a buyout. Moussatos noted that Celgene said it expects annual peak sales for Receptos' Ozanimod to reach about $4B-$6B for RMS and UC, making its acquisition price of $7.2BN only a bit more than about 1X peak sales without accounting for other possible indications or the rest of its pipeline. Moussatos, who told investors she sees "plenty" of potential upside to justify a rival bidder stepping in, reiterated the firm's Outperform rating and $348 acquisition value on Receptos shares.
07:04 EDTCELGCelgene volatility low into acquiring Receptos for about $7.2B
Subscribe for More Information
06:28 EDTCELGCelgene price target raised to $175 from $160 at Deutsche Bank
Subscribe for More Information
05:59 EDTCELGPiper views Receptos buyout as good for Arena
Piper Jaffray analyst Edward Tenthoff views Celgene's (CELG) acquisition of Receptos (RCPT) as good for Arena Pharmaceuticals (ARNA). Tenthoff views Arena as a "derivative call" on the deal with the company's APD334 already showing dose-dependent decreases in circulating lymphocyte counts. Arena will also initiate Phase II studies in ulcerative colitis and Crohn's disease this year, the analyst points out. Receptos' ozanimod is being studied in Phase III trials for relapsing multiple sclerosis and ulcerative colitis. Tenthoff reiterates an Overweight rating on Arena with a $7.50 price target. The company has a market capitalization around $1B and closed yesterday up 8c to $4.47
05:52 EDTCELGReceptos deal 'another good move' for Celgene, says Piper Jaffray
Subscribe for More Information
July 14, 2015
19:05 EDTCELGOn The Fly: Pre-market Movers
UP AFTER EARNINGS: CSX (CSX), up 3.5%. ALSO HIGHER: Receptos (RCPT), up 10.2% following deal to be acquired by Celgene (CELG)... Celgene is up 5.8% after announcing acquisition of Receptos... Celsion (CLSN), up 8.8% after being initiated with a Buy at BTIG... Aratana Therapeutics (PETX), up 10% after results of pivotal study of AT-003. DOWN AFTER EARNINGS: Peregrine (PPHM), down 3%... Yum! Brands (YUM), down marginally. ALSO LOWER: Allegheny Technologies (ATI), down 9.3% after providing second quarter EPS guidance... Mead Johnson (MJN), down 4.8% after reducing fiscal 2015 EPS guidance.
18:18 EDTCELGCelgene sees Receptos team staying on board following acquisition
Subscribe for More Information
18:08 EDTCELGImmuno-oncolgy stocks advance after Receptos acquired by Celgene
Subscribe for More Information
18:07 EDTCELGCelgene sees Receptos deal accretive in 2019
18:06 EDTCELGCelgene downplays regulatory concerns in Receptos deal, sees closing in Q3
Subscribe for More Information
17:31 EDTCELGReceptos up about 10% following deal to be acquired by Celgene
Subscribe for More Information
17:30 EDTCELGCelgene up about 5% after announcing acquisition of Receptos
Subscribe for More Information
17:09 EDTCELGCelgene raises 2020 adjusted EPS view to exceed $13.00, up from prior $12.50
Subscribe for More Information
17:06 EDTCELGCelgene reports preliminary Q2 adjusted EPS approximately $1.23, consensus 1.14
Subscribe for More Information
17:04 EDTCELGCelgene raises FY15 adjusted EPS view to $4.75-$4.85 from $4.60-$4.75
Subscribe for More Information
17:02 EDTCELGCelgene to acquire Receptos for $232 per share in cash, or about $7.2B
Subscribe for More Information
16:59 EDTCELGCelgene to acquire Receptos for $232 per share in cash
10:22 EDTPFEEuropean Commission says Pfizer offers concessions for Hospira deal, Reuters say
Subscribe for More Information
06:04 EDTRHHBYRoche says atezolizumab met primary endpoint in IMvigor 210 trial
Roche announced that in the IMvigor 210 study, the investigational cancer immunotherapy atezolizumab shrank tumors -- objective response rate, ORR, the primary end point of this Phase II study -- in people with locally advanced or metastatic urothelial bladder cancer who had progressed on initial treatment. High amounts of PD-L1 expression by a person’s cancer correlated with increased response to the medicine. Adverse events were consistent with what has been previously observed for atezolizumab. Sandra Horning, M.D., chief medical officer and head of Global Product Development, said, “We plan to present results at an upcoming medical meeting and will discuss next steps with health authorities to bring a new treatment option to patients as soon as possible.” Last year, the U.S. FDA granted Breakthrough Therapy Designation for atezolizumab in people whose metastatic bladder cancer expressed PD-L1. This designation is designed to expedite the development and review of medicines intended to treat serious diseases. In addition to the IMvigor 210 study, Roche has an ongoing randomised Phase III study, IMvigor 211, comparing atezolizumab with standard-of-care chemotherapy in people who have relapsed UBC, and a planned Phase III study, IMvigor 010, that will evaluate atezolizumab compared with observation in people with early-stage muscle-invasive bladder cancer who are selected for PD-L1 expression and are at risk for recurrence.
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use